Get all premium features to the best stock analysis tool

BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark's blood-based assay. Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce crucial updates reinforcing the clinical translation of its liquid biopsy technology platform for early non-small cell lung cancer (NSCLC) screening and risk stratification with the publication of two new peer-reviewed scientific papers.